Immuno-Biological Laboratories Co., Ltd. (TYO:4570)
1,007.00
-5.00 (-0.49%)
Jun 3, 2026, 3:30 PM JST
TYO:4570 Balance Sheet
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash & Equivalents | 989 | 825 | 734 | 614 | 508 |
Cash & Short-Term Investments | 989 | 825 | 734 | 614 | 508 |
Cash Growth | 19.88% | 12.40% | 19.54% | 20.87% | -15.89% |
Receivables | 178 | 231 | 190 | 217 | 173 |
Inventory | 379 | 317 | 321 | 318 | 326 |
Other Current Assets | 23 | 17 | 17 | 16 | 122 |
Total Current Assets | 1,569 | 1,390 | 1,262 | 1,165 | 1,129 |
Property, Plant & Equipment | 213 | 191 | 135 | 119 | 120 |
Long-Term Investments | 226 | 150 | 151 | 149 | 455 |
Other Intangible Assets | 1 | 1 | 2 | - | - |
Long-Term Deferred Tax Assets | 145 | 112 | 67 | - | - |
Other Long-Term Assets | 1 | 1 | 1 | 1 | 1 |
Total Assets | 2,155 | 1,845 | 1,618 | 1,434 | 1,705 |
Accounts Payable | 2 | 3 | 4 | 5 | 3 |
Accrued Expenses | 34 | 33 | 31 | 25 | 17 |
Short-Term Debt | 142 | 140 | 135 | 130 | 125 |
Current Portion of Long-Term Debt | 16 | 29 | 16 | 5 | 4 |
Current Income Taxes Payable | 4 | 5 | 5 | 25 | 24 |
Other Current Liabilities | 78 | 71 | 66 | 62 | 55 |
Total Current Liabilities | 276 | 281 | 257 | 252 | 228 |
Long-Term Debt | 18 | 35 | 84 | 99 | 104 |
Pension & Post-Retirement Benefits | 13 | 10 | 7 | 4 | 3 |
Other Long-Term Liabilities | 5 | 5 | 5 | 1 | 2 |
Total Liabilities | 312 | 331 | 353 | 356 | 337 |
Common Stock | 50 | 50 | 50 | 3,029 | 3,029 |
Additional Paid-In Capital | 1,040 | 1,040 | 1,040 | 2,061 | 2,061 |
Retained Earnings | 754 | 425 | 176 | -4,009 | -3,720 |
Treasury Stock | -1 | -1 | -1 | -1 | -1 |
Comprehensive Income & Other | - | - | - | -2 | -1 |
Shareholders' Equity | 1,843 | 1,514 | 1,265 | 1,078 | 1,368 |
Total Liabilities & Equity | 2,155 | 1,845 | 1,618 | 1,434 | 1,705 |
Total Debt | 176 | 204 | 235 | 234 | 233 |
Net Cash (Debt) | 813 | 621 | 499 | 380 | 275 |
Net Cash Growth | 30.92% | 24.45% | 31.32% | 38.18% | -46.50% |
Net Cash Per Share | 87.29 | 66.68 | 53.58 | 40.80 | 29.53 |
Filing Date Shares Outstanding | 9.31 | 9.31 | 9.31 | 9.31 | 9.31 |
Total Common Shares Outstanding | 9.31 | 9.31 | 9.31 | 9.31 | 9.31 |
Working Capital | 1,293 | 1,109 | 1,005 | 913 | 901 |
Book Value Per Share | 197.89 | 162.56 | 135.82 | 115.75 | 146.88 |
Tangible Book Value | 1,842 | 1,513 | 1,263 | 1,078 | 1,368 |
Tangible Book Value Per Share | 197.78 | 162.45 | 135.61 | 115.75 | 146.88 |